During glaucoma, α2-macroglobulin accumulates in aqueous humor and binds to nerve growth factor, neutralizing neuroprotection

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5260-5265

  Bai, Yujing ^a   Sivori, Delia ^b,c   Woo, Sang B ^d   Neet, Kenneth E ^d   Fabian Lerner, S ^b,c   Uri Saragovi, H ^a,e  

^a MCGILL UNIVERSITY   (Canada)

^b FAVALORO UNIVERSITY   (Argentina)

^c Fundacion para el Estudio del Glaucoma   (Argentina)

^d ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; NERVE GROWTH FACTOR; PROTEIN TYROSINE KINASE A; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; NEUROPROTECTIVE AGENT;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; CATARACT; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GLAUCOMA; HUMAN; HUMAN TISSUE; INTRAOCULAR PRESSURE; MALE; NEUROTOXICITY; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RETINA; RETINA GANGLION CELL; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; ANIMAL; CELL STRAIN; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TISSUE DISTRIBUTION; WISTAR RAT;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; ANIMALS; AQUEOUS HUMOR; BLOTTING, WESTERN; CELL DEATH; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENTS; PC12 CELLS; RATS; RATS, WISTAR; RECEPTOR, TRKB; RETINA; SURFACE PLASMON RESONANCE; TISSUE DISTRIBUTION;

EID: 80052618229     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6691     Document Type: Article

References (34)

1. Friedman DS, Cramer J, Quigley H. A more proactive approach is needed in glaucoma care. Arch Ophthalmol. 2005;123:1134-1135.
2. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNELpositive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031-1035.
3. Rudzinski M, Saragovi HU. Glaucoma: validated and facile in vivo experimental models of a chronic neurodegenerative disease for drug development. Curr Med Chem. 2005;5:43-49.
4. Hart Jr WM, Becker B. The onset and evolution of glaucomatous visual field defects. Ophthalmology. 1982;89:268-279.
5. Kwon YH, Kim YI, Pereira ML, Montague PR, Zimmerman MB, Alward WL. Rate of optic disc cup progression in treated primary open-angle glaucoma. J Glaucoma. 2003;12:409-416.
6. O'Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol. 1991;111:491-500.
7. Kass MA, Gordon MO, Hoff MR, et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch Ophthalmol. 1989;107:1590-1598.
8. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis. 2004;6(6 suppl):S61-S74.
9. Halpern DL, Grosskreutz CL. Glaucomatous optic neuropathy: mechanisms of disease. Ophthalmol Clin North Am. 2002;15:61-68.
10. Farkas RH, Grosskreutz CL. Apoptosis, neuroprotection, and retinal ganglion cell death: an overview. Int Ophthalmol Clin. 2001;41:111-130.
11. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41:764-774.
12. Ko M, Hu D, Ritch R, Sharma SC. The combined effect of BDNF and a free radical scavanger in experimental glaucoma. Invest Ophtalmol Vis Sci. 2000;41:2967-2971.
13. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci. 2006;26:12633-12641.
14. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32:42-50.
15. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42:1787-1794.
16. Wax MB, Tezel G. Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol Neurobiol. 2002;26:45-55.
17. McKinnon SJ. Glaucoma: ocular Alzheimer's disease? Front Biosci. 2003;8:S1140-S1156.
18. Shi Z, Rudzinski M, Meerovitch K, et al. alpha 2 macroglobulin is a mediator of retinal ganglion cell death in glaucoma. J Biol Chem. 2008;283:29156-29165.
19. Bai Y, Dergham P, Nedev H, et al. In chronic and in acute models of retinal neurodegeneration TrkA activity is neuroprotective while p75NTR activity is neurotoxic through a paracrine mechanism. J Biol Chem. 2010;285:39392-39400.
20. Bai Y, Shi Z, Zhuo Y, et al. In glaucoma the up-regulated truncated TrkC. T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2010;51:6639-6651.
21. Bai Y, Xu J, Brahimi F, Zhuo Y, Sarunic MV, Saragovi HU. An agonistic anti-TrkB mAb, but not BDNF, causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma. Invest Ophthalmol Vis Sci. 2010;51:4722-4731.
22. Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Dev Neurobiol. 2007;67:884-894.
23. Laquis S, Chaudhary P, Sharma S. The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res. 1998;784:100-104.
24. Moore C, Epley D, Milne S, Morrison J. Long-term noninvasive measurement of intraocular pressure in the rat eye. Curr Eye Res. 1995;14:711-717.
25. Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J Neurobiol. 2004;58:341-354.
26. Naskar R, Wissing M, Thanos S. Detection of early neuron degeneration and accompanying microglial responses in the retina of a rat model of glaucoma. Invest Ophthalmol Vis Sci. 2002;43:2962-2968.
27. Mahapatra S, Mehta H, Woo SB, Neet KE. Identification of critical residues within the conserved and specificity patches of nerve growth factor leading to survival or differentiation. J Biol Chem. 2009;284:33600-33613.
28. James K, van den Haan J, Lens S, Farmer K. Preliminary studies on the interaction of TNF alpha and IFN gamma with alpha 2-macroglobulin. Immunol Lett. 1992;32:49-57.
29. Wu SM, Patel DD, Pizzo SV. Oxidized alpha2-macroglobulin (alpha2M) differentially regulates receptor binding by cytokines/ growth factors: implications for tissue injury and repair mechanisms in inflammation. J Immunol. 1998;161:4356-4365.
30. Maliartchouk S, Debeir T, Beglova N, Cuello AC, Gehring K, Saragovi HU. Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. J Biol Chem. 2000;275:9946-9956.
31. Maliartchouk S, Saragovi HU. Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. J Neurosci. 1997;17:6031-6037.
32. Lambiase A, Centofanti M, Micera A, et al. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 1997;235:780-785.
33. Saragovi HU, Hamel E, Di Polo A. A neurotrophic rationale for the therapy of neurodegenerative disorders. Current Alzheimer research. 2009;6:419-423.
34. Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci U S A. 2009;106: 13469-13474.